awmsg logo



desmopressin acetate (Noqdirna®)


Reference No. 3282

Publication date:
17/10/2017


Appraisal information

desmopressin acetate (Noqdirna®) 25 micrograms sublingual tablet
desmopressin acetate (Noqdirna®) 50 micrograms sublingual tablet


Company: Ferring Pharmaceuticals (UK)
BNF category: Endocrine system
NMG meeting date: 07/06/2017
AWMSG meeting date: 13/09/2017
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1617
Ministerial ratification: 16/10/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Desmopressin acetate (Noqdirna®) for the treatment of nocturia due to idiopathic nocturnal polyuria in adults is recommended for restricted use within NHS Wales. Desmopressin acetate (Noqdirna®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of nocturia due to idiopathic nocturnal polyuria in adults: • aged over 65, for whom treatment options are currently limited. Desmopressin acetate (Noqdirna®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download